Bioqual (BIOQ) AI Stock Analysis

• Market Cap: $34.64M
• Dividend Yield: N/A
• Average Volume (3M): 223.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.12
• Revenue Growth: -14.29%
• EPS Growth: 43.04%
• Country: US
• Employees: 278
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.28
• Shares Outstanding: 893,838
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 223
• PEG Ratio: 0.12
• Price to Book (P/B): 1.11
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 14.87
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 0.78
• Enterprise Value/Gross Profit: -20.16
• Enterprise Value/Ebitda: 21.51
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $40.00 ▲(3.23% Upside)

Bioqual's overall stock score is primarily impacted by its financial performance challenges, including declining revenues and negative profit margins. Technical analysis further indicates bearish trends, with the stock trading below key moving averages. The valuation is also a concern due to a negative P/E ratio, reflecting unprofitability. These factors collectively result in a lower overall score.

Positive Factors

Cash Flow Recovery

The significant recovery in free cash flow suggests improved operational efficiency and better cash management, which can support future investments and debt servicing, enhancing long-term financial stability.

Stable Capital Structure

A manageable debt-to-equity ratio indicates a solid capital structure, providing the company with financial flexibility to navigate operational challenges and invest in growth opportunities.

Efficient Cash Generation

Efficient cash generation relative to net income highlights the company's ability to convert profits into cash, which is crucial for funding operations, paying down debt, and supporting strategic initiatives.

Negative Factors

Declining Revenues

The significant decline in revenues indicates potential issues with demand or competitive positioning, which could impact the company's ability to sustain operations and invest in growth over the long term.

Negative Profit Margins

Negative profit margins suggest operational inefficiencies and cost management issues, which could erode financial health and limit the company's ability to reinvest in its business.

Profitability Issues

Negative return on equity indicates that the company is not generating sufficient returns on shareholder investments, which could deter future investment and hinder growth prospects.

Bioqual Business Overview & Revenue Model

Company Description

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.

How the Company Makes Money

Bioqual generates revenue through multiple key streams, primarily by offering specialized preclinical research services and custom animal models to pharmaceutical and biotech companies. The company charges clients for access to its laboratory facilities, expertise, and proprietary technologies, which are essential for drug development and testing. Additionally, Bioqual may enter into strategic partnerships and collaborations with other research institutions or companies, allowing it to secure funding and expand its service offerings. The company also benefits from long-term contracts and repeat business from established clients, contributing to a steady revenue flow.

Bioqual Financial Statement Overview

Summary

Bioqual's financial performance is challenged by declining revenues and negative profit margins, as indicated by the income statement. The balance sheet is moderately stable with a manageable debt-to-equity ratio, but profitability issues have impacted return on equity. Cash flow improvements are a positive sign, though historical volatility suggests caution.

Income Statement

Bioqual's income statement reveals a concerning trend with declining revenues and negative profit margins. The gross profit margin and net profit margin have turned negative in the latest year, indicating operational challenges. Revenue has decreased significantly by 26.5% compared to the previous year, highlighting a need for strategic adjustments to reverse this trend.

Balance Sheet

The balance sheet shows moderate financial stability with a manageable debt-to-equity ratio of 0.46. However, the return on equity has turned negative, reflecting recent profitability issues. The equity ratio remains healthy, suggesting a solid capital structure despite recent setbacks.

Cash Flow

Cash flow analysis indicates a strong recovery in free cash flow, with a growth rate of 741.87%. The operating cash flow to net income ratio is positive, suggesting efficient cash generation relative to net income. However, historical volatility in free cash flow growth poses a potential risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	48.87M	48.87M	58.59M	62.66M	66.15M	57.68M
Gross Profit	-1.90M	-1.90M	7.43M	12.60M	13.01M	13.97M
EBITDA	1.78M	509.61K	3.03M	6.97M	14.76M	13.07M
Net Income	-1.05M	-1.05M	483.48K	835.55K	5.26M	6.33M
Balance Sheet
Total Assets	57.12M	57.12M	56.59M	61.32M	63.34M	53.42M
Cash, Cash Equivalents and Short-Term Investments	17.85M	17.85M	15.59M	7.28M	2.18M	7.72M
Total Debt	16.54M	16.54M	3.59M	18.61M	18.72M	14.62M
Total Liabilities	20.96M	20.96M	18.94M	23.70M	25.67M	19.89M
Stockholders Equity	36.15M	36.15M	37.65M	37.61M	37.67M	33.53M
Cash Flow
Free Cash Flow	2.71M	2.71M	8.76M	5.99M	-4.57M	-2.26M
Operating Cash Flow	2.94M	2.94M	9.36M	8.23M	313.36K	2.15M
Investing Cash Flow	-238.78K	-238.78K	-597.13K	-2.24M	-4.73M	-3.70M
Financing Cash Flow	-447.21K	-447.21K	-447.21K	-894.42K	-1.12M	-983.86K

Bioqual Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 38.75
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Neutral. The current price of 38.75 is above the 20-day moving average (MA) of 38.57, above the 50-day MA of 38.74, and below the 200-day MA of 44.02, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.69 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIOQ.

Bioqual Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	56 Neutral	$45.66M	-30.80	-9.76%	―	30.95%	59.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDSX	50 Neutral	$64.28M	-1.84	-302.55%	―	22.29%	31.93%
VNRX	49 Neutral	$41.75M	-1.39	―	―	14.48%	36.83%
BIOQ	48 Neutral	$34.64M	-55.76	-2.84%	―	-14.29%	43.04%
NOTV	43 Neutral	$21.25M	-0.27	-44.77%	―	4.54%	47.11%
BNGO	40 Underperform	$16.18M	-0.10	-78.22%	―	-13.84%	88.80%